Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
Globally, BRUKINSA is approved in more than 70 countries
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
Subscribe To Our Newsletter & Stay Updated
